• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

CSF1R regulates schizophrenia-related stress response and vascular association of microglia/macrophages

byRhianna DavisandAlex Chan
August 12, 2023
in Chronic Disease, Neurology, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to healthy controls, participants with a first episode of schizophrenia had reduced expression of a microglia-associated protein, CSF1R. 

2. CSF1R inhibition worsened anxiety behaviors in mice exposed to chronic unpredictable stress. 

Evidence-rating level: 3 (Average)

Psychosocial stress is thought to contribute to the development of schizophrenia, mainly for those with underlying genetic susceptibility. Though microglia are important regulators of stress in the brain, the role of microglia in the development of schizophrenia has not previously been thoroughly investigated. Colony stimulating factor 1 receptor (CSF1R) is a protein expressed by microglia. In this study, 51 participants with a first episode of schizophrenia (FES) were paired with 46 healthy age and sex-matched controls (HC) with elevated perceived stress. Researchers measured CSF1R RNA and protein levels in the participant’s blood. In addition, participants underwent brain MRIs to compare anatomy between FES and HC groups. Finally, the researchers studied a mouse model of chronic unpredictable stress, combined with a CSF1R inhibitor, and examined the rodent’s anxiety behaviors. The FES group had lower levels of CSF1R mRNA and protein compared to the HC group (p < 0.05). Additionally, their superior frontal and parahippocampal gyrus volumes were significantly smaller compared to the HC group. In mice, the CSF1R inhibitors enhanced anxiety behaviors during chronic unpredictable stress. As well, CSF1R inhibition reduced the expression of genes involved in brain angiogenesis (p < 0.001) in mice. This study demonstrates that CSF1R may be an important regulator of stress responses and the development of schizophrenia. Limitations of this study include the small sample size and cross-sectional study design. Future research may examine the CSF1R expression in a larger sample size or via a longitudinal study. As well, this study included exclusively male rodents in the creation of their mouse model. Future work should aim to better encapsulate human populations by incorporating both male and female mice. Overall, this study suggests that CSF1R could be a novel therapeutic target for schizophrenia treatments in the future. 

Click to read the study in BMC Medicine

Image: PD

RELATED REPORTS

Inebilizumab improves outcome in patients generalized myasthenia gravis

Cerebral embolic protection does not decrease stroke incidence in TAVI patients

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: neurologyneuropsychiatrypsychiatrypsychopharmacologyschizophrenia
Previous Post

Dupilumab reduces the number exacerbations in patients with COPD and type two inflammation

Next Post

Mental health disorders more prevalent amongst adults with inflammatory skin conditions

RelatedReports

Age and number of islet autoantibodies associated with diabetes risk
Neurology

Inebilizumab improves outcome in patients generalized myasthenia gravis

July 10, 2025
Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation
Cardiology

Cerebral embolic protection does not decrease stroke incidence in TAVI patients

July 8, 2025
Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
Weekly Rewinds

2 Minute Medicine Rewind July 7, 2025

July 10, 2025
Next Post
Eczema more prevalent among older adults than previously thought

Mental health disorders more prevalent amongst adults with inflammatory skin conditions

2 Minute Medicine Rewind August 14, 2023

Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain

Moral injury is associated with the overall wellbeing of healthcare professionals

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
  • Structured exercise intervention improves survival in colon cancer patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.